In March 2026, Codexis reported that Q4 2025 revenue rose to US$38.92 million with net income of US$9.6 million, while full-year revenue reached US$70.39 million alongside a reduced net loss and new ...
Central government has included a US based quadrivalent vaccine, Gardasil in the national immunisation program ...
PepsiCo, Inc. (NASDAQ:PEP) is one of the stocks Jim Cramer evaluated, along with the fragile food market. A caller asked if it is time to get out of the stock, and Cramer replied: No… This is at the ...
A 2025 EHV-1 outbreak in Texas highlighted event-wide risks of inadequate biosecurity. Key measures: early fever detection, ...
Immutep and the Australian biotech’s investors have been caught off guard by the unexpected failure of its LAG-3 candidate in a phase 3 study. | Immutep and the Australian biotech’s investors have ...
Merck & Co., Inc. (NYSE:MRK) has been on a strong recovery run, gaining 23% over the past year and 8% year-to-date, though the stock has pulled back some, now well below its 52-week high of $125.14.
Merck & Co. Inc. (NYSE:MRK) ranks among the 14 safe stocks to buy now for a starter stock portfolio. Merck & Co. Inc. (NYSE:MRK) ranks among the 14 safe stocks to buy now for a starter stock portfolio ...
Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care ...
7don MSN
Tempus AI, Inc. (TEM) announces strategic deal with Merck to fast-track AI-driven precision medicine
Tempus AI, Inc. (NASDAQ:TEM) is among the ARK Invest Stock Portfolio: Top 10 Stock Picks for 2026. On March 3, the company ...
The company anticipates currency headwinds would continue to weigh on its earnings this year, as the life-sciences and chemical company prepares for a leadership change.
After delivering solid sales growth in a difficult 2025, Germany’s Merck KGaA may have a tougher go of things this year, which the company is crediting in part to a predicted onslaught of U.S.
Merck KGaA forecast a sluggish year ahead, with the possibility of falling profits, as generic competition for its multiple ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results